Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 13/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5505947 | 0.79 | SIGMAR1 (0.47) | SIGMAR1NPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL6009865 | 0.76 | KCNA5 (0.42) | TSHR | |
| SCHEMBL5506848 | 0.75 | NR3C1 (0.41) | CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5505984 | 0.74 | SIGMAR1 (0.49) | SIGMAR1NPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL916682 | 0.74 | SIGMAR1 (0.65) | SIGMAR1CYP1A2CYP2D6TSHR | |
| SCHEMBL18775653 | 0.73 | SMN1; SMN2 (0.41) | CYP1A2CYP3A4TSHRTAAR1 | |
| SCHEMBL15819038 | 0.73 | SIGMAR1 (0.54) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| Methamphetamine SCHEMBL28548051 | 0.72 | SIGMAR1 (0.78) | SIGMAR1NPC1RAB9ATAAR1 | |
| Levmetamfetamine SCHEMBL712604 | 0.72 | SIGMAR1 (0.78) | SIGMAR1NPC1RAB9ATAAR1 | |
| Methamphetamine SCHEMBL712603 | 0.72 | SIGMAR1 (0.78) | SIGMAR1NPC1RAB9ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828111-A2 | METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | US | disclosed |
| WO-2006059252-A2 | METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | APP, PSEN1, TTR | SIGMAR1 3705/4885NPC1 37/4885RAB9A 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.